March issue of PharmaTimes Magazine is out now
How to… / Hold an inspirational meeting
We take a look at some innovative alternatives SmartTech / Droning on
Could drones have a place in healthcare? We investigate
Last month’s SmartDeals
You let us know your thoughts
we take a look at EU clinical trials transparency
News from the technology and marketing world
Business Insight / Royal Bank of Scotland: “no two businesses are the same”
RBS’ pharma team talks to us about how they are continuing to support the industry – with specialist insight
Cover story/Adherence / Use it or lose it
It doesn’t matter how good your medicine is or how well it performs in clinical trials if patients aren’t taking it as recommended
Medicines Optimisation / Taking your medicine
Is the current healthcare system helping or hindering medicines optimisation?
Health Focus / The challenge of schizophrenia
There is still much to be done to help patients with this disease
Emerging Markets / MINT Selection
Forget BRIC, the new acronym is MINT – Mexico, Indonesia, Nigeria, Turkey – as the latest emerging markets on pharma’s radar
Business Insight / Ashfield Healthcare – supporting customer and patient outcomes
What makes Ashfield Healthcare unique?
Patient Files / “Think of us as partners and not as subjects”
One patient’s experience of being diagnosed with whooping cough
Click here to see the latest PharmaTimes Magazine
To subscribe go to www.pharmatimes.com/subscribe; digital available from:
Outcomes: a gamechanger for pharma
Patient-recorded outcome measures are likely to become a key part of how healthcare is provided, funded and managed. But is industry ready?
Healthcare Writer Lynne Taylor
The British government’s determination to place health outcomes at the heart of NHS decision-making presents UK-based drugmakers with a unique and potentially huge advantage over their global competitors.
Working in collaboration with the NHS to identify a product’s true value – in other words its value to the patient – has the potential to boost levels of medicines uptake and could also lead to products arriving earlier to market, both in the UK and overseas, a PharmaTimes business meeting was told recently. Leading these potentially game-changing opportunities is the NHS patient-recorded outcome measures programme, which began in 2009.
Innovative drugmakers have included PROMs in their clinical trials for many years, and the data have also long been used in observational studies and population health surveys. “We have decades of experience using these instruments and pharma is way ahead of the game. The fact they are now being measured in healthcare systems changes everything,” Professor Nancy Devlin, research director at the Office of Health Economics told the meeting. Indeed, PROMs are likely to become a key part of how all healthcare is provided, funded and managed, The King’s Fund healthcare policy think-tank has forecast.
So what exactly are PROMs and why should this matter to pharma? You can find out by reading the full article online here
See what's coming up in the March issue [PDF]
Visions 2014 supplement
Creating a balance between
reimbursement and innovation
How to plan early
What more does pharma need to do?
We asked you what the big developments in 2014 will be?
Change is key to opportunity
What to adapt for
Future-proofing the sales team
An example of a new R&D model
Visions in a nutshell
The complete Visions 2014 supplement PDF is available to download
Subscription is free to qualifying UK subscribers
To read articles in full and features in the magazine, why not subscribe
Average circulation Jan - Dec 2013: 23,178